SOMATOSTATIN RECEPTOR POSITIVE
Clinical trials for SOMATOSTATIN RECEPTOR POSITIVE explained in plain language.
Never miss a new study
Get alerted when new SOMATOSTATIN RECEPTOR POSITIVE trials appear
Sign up with your email to follow new studies for SOMATOSTATIN RECEPTOR POSITIVE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New radioactive drug targets Hard-to-Treat gut and adrenal tumors
Disease control Recruiting nowThis study tests a new radioactive drug, [212Pb]VMT-alpha-NET, in people with advanced gastrointestinal neuroendocrine tumors or pheochromocytoma/paragangliomas that have already been treated with radiation therapy. The drug is designed to attach to a protein on the surface of th…
Matched conditions: SOMATOSTATIN RECEPTOR POSITIVE
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New radiation drug targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests a radioactive drug that seeks out and delivers radiation directly to cancer cells with a specific protein (somatostatin receptor). It is for adults with advanced lung, kidney, head and neck, digestive tract, or adrenal gland tumors that cannot be remo…
Matched conditions: SOMATOSTATIN RECEPTOR POSITIVE
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New hope for kids with tough cancers: targeted radiation trial launches
Disease control Recruiting nowThis early-stage trial tests a radioactive drug (Lu-177 edotreotide) in children aged 2 to 17 with cancers that have a specific marker (SSTR-positive). The goal is to find the right dose and check safety. About 20 children whose cancer has returned or not responded to prior treat…
Matched conditions: SOMATOSTATIN RECEPTOR POSITIVE
Phase: PHASE1 • Sponsor: ITM Solucin GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC